How can we better justify the cost of our medicines to payers?
What and how can innovative agreements and reimbursement mechanisms be used?
How can we better convey the value patients and families experience from new innovative treatments to payers, for example, but not limited to rare disease medication?
How to navigate the regulatory and HTA requirements to gain faster access?
Regulatory Frameworks
Workshop
Speaker
Karl-Johann Myren
Senior Director, Head of HEOR International & Japan region, Alexion
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services.